Shenzhen Salubris Pharmaceuticals (002294) Fundamentals 2026 — P/E 57.0x, Revenue Analysis | SniperIQ
Shenzhen Salubris Pharmaceuticals (002294) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥38.4B, trading at ¥34.41 on the SHZ. This SniperIQ fundamentals page covers Shenzhen Salubris Pharmaceuticals's valuation (P/E 57.0x, P/B 4.2x), profitability (net margin 15.0%), revenue (¥4.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shenzhen Salubris Pharmaceuticals's market cap?
Shenzhen Salubris Pharmaceuticals (002294) has a market capitalization of approximately ¥38.4B, trading at ¥34.41 on the SHZ. Market cap moves with the live share price.
What is Shenzhen Salubris Pharmaceuticals's P/E ratio?
Shenzhen Salubris Pharmaceuticals's trailing twelve-month P/E ratio is 57.0x, with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shenzhen Salubris Pharmaceuticals?
Shenzhen Salubris Pharmaceuticals runs a net profit margin of 15.0%, a gross margin of 74.8%, and an operating margin of 11.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shenzhen Salubris Pharmaceuticals generate?
Shenzhen Salubris Pharmaceuticals reported revenue of ¥4.3B for fiscal year 2025, with net income of ¥652M and earnings per share (EPS) of 0.58. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shenzhen Salubris Pharmaceuticals pay a dividend?
Shenzhen Salubris Pharmaceuticals offers a trailing dividend yield of about 1.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shenzhen Salubris Pharmaceuticals financially healthy?
Shenzhen Salubris Pharmaceuticals carries a debt-to-equity ratio of 0.07x and a current ratio of 2.34x, with a market beta of -0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shenzhen Salubris Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shenzhen Salubris Pharmaceuticals (002294) the key facts are: market cap ¥38.4B, P/E 57.0x, revenue ¥4.3B, 52-week range 29.25-70.99. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shenzhen Salubris Pharmaceuticals's full fundamentals live
Get Shenzhen Salubris Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.